人工智能将彻底改变IBD临床试验:全面审查
Rocio Sedano1,2,3, Virginia Solitano2,4, Sudheer K Vuyyuru1
1Division of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.
Therapeutic advances in gastroenterology
|February 25, 2025
概括
人工智能 (AI) 可以通过提高效率和个性化治疗来彻底改变炎症性肠病 (IBD) 临床试验. 解决数据整合和偏见等挑战是加速IBD患者新疗法的关键.
科学领域:
- 临床研究是临床研究.
- 医学中的人工智能
- 炎症性肠病 (IBD) 的治疗方法
背景情况:
- 炎症性肠病 (IBD) 临床试验在效率,准确性和个性化方面面临挑战.
- 人工智能 (AI) 为增强IBD研究提供了变革性的潜力.
研究的目的:
- 探索AI驱动技术在IBD临床试验中的应用.
- 确定人工智能如何改善患者招募,试验设计,数据分析和个性化治疗策略.
- 讨论在IBD试验中成功整合AI的挑战和必要步骤.
主要方法:
- 审查人工智能技术,包括机器学习 (ML),自然语言处理和预测分析.
- 整合多主题数据,电子健康记录和成像数据.
- 分析AI在简化试验阶段中的作用,从目标识别到患者监测.
主要成果:
- 人工智能可以提高IBD试验的效率,准确性和个性化,加速新疗法发现.
- 人工智能有助于简化试验流程,发现分子目标和个性化策略.
- 显著的挑战包括数据集成,患者隐私,监管标准以及由于缺乏多样化的数据集而造成的潜在AI偏见.
结论:
- 克服技术,道德和监管障碍对于在IBD试验中采用AI至关重要.
- 标准化数据,跨学科合作和道德框架对于包容和准确的AI实施至关重要.
- 人工智能具有显著的潜力,可以提高IBD临床试验的效率,公平性和有效性,最终有利于患者的护理.
相关概念视频
iPS Cell Differentiation
2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K
EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
131
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
131
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
295
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
295
Inflammatory Bowel Disease IV: Pharmacological Management
89
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
89
